Welcome to our dedicated page for Supernus Pharmaceuticals news (Ticker: $SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Supernus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Supernus Pharmaceuticals's position in the market.
Supernus Pharmaceuticals, Inc. reported strong financial results for the first quarter of 2024, with net sales of Qelbree® increasing by 75% to $45.1 million. Total revenues were $143.6 million, with a 12% increase in revenues excluding Trokendi XR® and Oxtellar XR® net product sales. The Company reiterates its full year 2024 financial guidance, including total revenue guidance of $580 - $620 million. Key product pipeline updates include SPN-830 for Parkinson's disease and SPN-820 for depression. The Company also announced the initiation of a Phase I study for SPN-443 for ADHD/CNS.
M8 Pharmaceuticals, an Acino company, has signed an exclusive licensing agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) to commercialize Qelbree® (Viloxazine XR) in Latin America. Qelbree® is an extended-release capsule approved to treat ADHD in the US. This partnership aims to provide innovative treatment options for patients in Latin America.
Busy Philipps partners with Supernus Pharmaceuticals to share her experience with ADHD and treatment with Qelbree, a non-stimulant medication. The partnership aims to raise awareness during Mental Health Awareness Month for the millions of adults living with ADHD in the US.
